New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:33 EDTCVMCEL-SCI reports continued increase in patient enrollment in Phase III trial
CEL-SCI Corporation announced that during the month of May the company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014. So far, a total of 197 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
09:03 EDTCVMCEL-SCI receives regulatory clearance to expand Phase III trial
CEL-SCI Corporation announced the Romanian Ministry of Health has cleared the company to begin patient enrollment and conduct its Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikinein Romania. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use